RTI Health Solutions

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. (2022) Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Journal article Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. (2022) Lip GYH, Kotalczyk A, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Journal article, Erratum Treatment preferences for preventive interventions for rheumatoid arthritis: Protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project (2021) Falahee M, Simons G, Disantostefano RL, Valor Méndez L, Radawski C, Englbrecht M, Schölin Bywall K, et al. Journal article, Original article Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies (2019) Coates LC, Wallman JK, McGonagle D, Schett G, McInnes IB, Mease PJ, Rasouliyan L, et al. Journal article SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2019) Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al. Conference contribution IMPACT OF SECUKINUMAB TREATMENT ON PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE: POOLED DATA FROM FUTURE 2 AND FUTURE 3 PHASE 3 STUDIES (2019) Mcinnes IB, Wallman JK, Schett G, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE - POOLED ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3) (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Gaillez C, Fasth AE Conference contribution SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2018) Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al. Conference contribution Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study (2018) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Journal article